Fig. 3: Gene expression changes after UNC0642 treatment assayed using Nanostring CAR-T characterization panel.

A Volcano plot of changes in gene expression assayed with Nanostring CAR-T characterization panel for T cells after drug treatment. Genes with a significant (p < 0.05) increase of greater than 1.5 fold are in red, and less than 1.5 fold in green. Data are analyzed with two-sided t tests, N = 3 biologically independent donors. B qPCR validation of changes in gene expression after drug treatment. Data are represented as fold-change from untreated. Data are analyzed with two-sided one-sample t test against a hypothetical mean of 1, N = 5 biologically independent donors. C ChIP-qPCR validation of changes in H3K9me2 at CCL23 and CCL18 after drug treatment. Data are represented as fold-change from untreated. Data are analyzed with two-sided one-sample t test against a hypothetical mean of 1, N = 3 biologically independent donors. D Secreted CCL18 concentration after drug treatment assayed by ELISA. N = 3 biologically independent donors. E Secreted CCL18 concentration at 120 h after drug treatment. Data for individual donors are shown. F Change in pathway scores after drug treatment. Pathway scores were defined using nSolver Advanced analysis software. Data are from 3 different donor T cells. G Oxygen consumption rate (OCR) of untreated and UNC0642-treated T cells. ATP-linked respiration, maximal respiration and spare capacity were calculated from the OCR plot. Data are analyzed with two-way ANOVA with multiple comparisons, N = 3 biologically independent donors. H Extracellular acidification rate (ECAR) for untreated and UNC0642-treated T cells. Glycolysis, glycolytic capacity and glycolytic reserve were calculated from the ECAR plot. Data are analyzed with two-way ANOVA with multiple comparisons, N = 3 biologically independent donors. All data are shown as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Source data are provided as a Source Data file.